Novo Nordisk A/S $NVO Shares Sold by Boston Common Asset Management LLC

Boston Common Asset Management LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 20.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,484 shares of the company’s stock after selling 17,268 shares during the period. Boston Common Asset Management LLC’s holdings in Novo Nordisk A/S were worth $3,689,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. True Wealth Design LLC boosted its holdings in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the last quarter. NewSquare Capital LLC grew its stake in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the second quarter worth $37,000. Maseco LLP purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $39,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent analyst reports. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Wednesday, January 14th. Morgan Stanley restated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. HSBC reaffirmed a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group dropped their price objective on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $56.21.

Novo Nordisk A/S Trading Down 2.3%

NYSE NVO opened at $59.29 on Thursday. The company has a market capitalization of $264.71 billion, a PE ratio of 17.23 and a beta of 0.66. The firm’s fifty day simple moving average is $51.59 and its 200-day simple moving average is $54.80. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Expanded cell‑therapy tie-up with Aspect Biosystems positions Novo to pursue potential curative diabetes treatments — a long‑horizon revenue upside beyond GLP‑1 drugs. Novo Nordisk expands diabetes cell therapy partnership with Aspect Biosystems
• Positive Sentiment: Launch of an oral Wegovy could expand market reach versus injectable GLP‑1s, helping defend share as competitors multiply. Is Oral Wegovy a Game Changer for Novo Nordisk?
• Positive Sentiment: Analyst forecasts and industry coverage continue to highlight massive sales potential for Ozempic/Wegovy (multibillion dollar tailwind), supporting longer‑term earnings expectations. Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)
• Positive Sentiment: New Ozempic ad campaign aims to differentiate the brand amid competition, which can help sustain prescribing and consumer preference. Novo Nordisk Aims to Set Ozempic Apart From Other GLP-1s in New Ad Campaign
• Neutral Sentiment: Mixed market write‑ups and valuation checks note a sharp rebound from prior lows, leaving valuation and upside debate active among investors. Assessing Novo Nordisk Valuation After A Sharp Rebound
• Negative Sentiment: Dr. Reddy’s plans to launch a generic Ozempic in India in March after patent expiry — an immediate revenue headwind in a large market and a signal of rising generic pressure in other jurisdictions. Dr Reddy’s to Start Selling Generic Ozempic in India From March
• Negative Sentiment: Industry commentary from JPM highlighted drug‑pricing scrutiny and looming patent cliffs, reinforcing downside risk to near‑term margins and growth. Drug pricing, patent losses and deals: Here’s what pharma execs see ahead
• Negative Sentiment: Market headlines and brief notes pointing to a pullback in the stock this session have weighed on sentiment, contributing to higher trading volume and short‑term selling. Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.